Euroespes Résultats passés
Passé contrôle des critères 0/6
Euroespes's earnings have been declining at an average annual rate of -519.8%, while the Life Sciences industry saw earnings growing at 25.2% annually. Revenues have been growing at an average rate of 0.09% per year.
Informations clés
-519.8%
Taux de croissance des bénéfices
-565.1%
Taux de croissance du BPA
| Life Sciences Croissance de l'industrie | 26.8% |
| Taux de croissance des recettes | 0.08% |
| Rendement des fonds propres | -18.3% |
| Marge nette | -29.5% |
| Dernière mise à jour des bénéfices | 31 Dec 2022 |
Mises à jour récentes des performances passées
Pas de mise à jour
Ventilation des recettes et des dépenses
Comment Euroespes gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Dec 22 | 4 | -1 | 1 | 0 |
| 30 Sep 22 | 4 | -1 | 0 | 0 |
| 30 Jun 22 | 4 | 0 | 0 | 0 |
| 31 Mar 22 | 4 | 0 | 0 | 0 |
| 31 Dec 21 | 4 | 0 | 0 | 0 |
| 30 Sep 21 | 4 | 0 | 0 | 0 |
| 30 Jun 21 | 3 | 0 | 0 | 0 |
| 31 Mar 21 | 3 | 0 | 0 | 0 |
| 31 Dec 20 | 3 | 0 | 0 | 0 |
| 30 Sep 20 | 3 | -1 | 0 | 0 |
| 30 Jun 20 | 2 | -1 | 0 | 0 |
| 31 Mar 20 | 2 | -1 | 0 | 0 |
| 31 Dec 19 | 3 | -1 | 0 | 0 |
| 30 Sep 19 | 3 | -1 | 0 | 0 |
| 30 Jun 19 | 3 | -1 | 0 | 0 |
| 31 Mar 19 | 3 | -1 | 0 | 0 |
| 31 Dec 18 | 3 | 0 | 0 | 0 |
| 30 Sep 18 | 3 | 0 | 0 | 0 |
| 30 Jun 18 | 3 | 0 | 0 | 0 |
| 31 Mar 18 | 3 | 0 | 0 | 0 |
| 31 Dec 17 | 3 | 0 | 0 | 0 |
| 30 Sep 17 | 4 | 0 | 0 | 0 |
| 30 Jun 17 | 4 | 0 | 0 | 0 |
| 31 Mar 17 | 4 | 0 | 0 | 0 |
| 31 Dec 16 | 3 | 0 | 0 | 0 |
| 30 Jun 16 | 3 | 0 | 0 | 0 |
| 31 Mar 16 | 3 | 0 | 0 | 0 |
| 31 Dec 15 | 3 | 0 | 0 | 0 |
| 30 Jun 15 | 3 | 0 | 0 | 0 |
| 31 Mar 15 | 3 | 0 | 0 | 0 |
| 31 Dec 14 | 3 | 0 | 0 | 0 |
| 31 Dec 13 | 3 | 0 | 0 | 0 |
Des revenus de qualité: EEP is currently unprofitable.
Augmentation de la marge bénéficiaire: EEP is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: Insufficient data to determine if EEP's year-on-year earnings growth rate was positive over the past 5 years.
Accélération de la croissance: Unable to compare EEP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: EEP is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (0.4%).
Rendement des fonds propres
ROE élevé: EEP has a negative Return on Equity (-18.34%), as it is currently unprofitable.